Exicure is an early-stage biotechnology company developing nucleic acid therapies targeting ribonucleic acid against validated targets to neurological disorders and hair loss. Co. is focus on realignment of its research and development resources to support the development of its preclinical program targeting SCN9A for neuropathic pain; the development of its partnered programs to develop Spherical Nucleic Acid, or SNA-based treatments in neuroscience targeting Huntington's disease and Angelman syndrome; the development of its partnered program to develop SNA-based treatments for hair loss disorders; and the research and development of other undisclosed therapeutic product candidates. We show 11 historical shares outstanding datapoints in our coverage of XCUR's shares outstanding history.
Understanding the changing numbers of XCUR shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like XCUR versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching XCUR by allowing them to research XCUR shares outstanding history
as well as any other stock in our coverage universe. |
Free XCUR Email Alerts:
Video: Shares Outstanding Importance
